DrugPatentWatch Database Preview
Mylan Pharms Inc Company Profile
What is the competitive landscape for MYLAN PHARMS INC, and when can generic versions of MYLAN PHARMS INC drugs launch?
MYLAN PHARMS INC has two hundred and sixty approved drugs.
There are nine US patents protecting MYLAN PHARMS INC drugs. There are twenty-nine tentative approvals on MYLAN PHARMS INC drugs.
There are one hundred and eighty patent family members on MYLAN PHARMS INC drugs in thirty-nine countries and five hundred and thirty-six supplementary protection certificates in fifteen countries.
Summary for Mylan Pharms Inc
| International Patents: | 180 |
| US Patents: | 9 |
| Tradenames: | 214 |
| Ingredients: | 204 |
| NDAs: | 260 |
Drugs and US Patents for Mylan Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Pharms Inc | ZIPRASIDONE HYDROCHLORIDE | ziprasidone hydrochloride | CAPSULE;ORAL | 202395-004 | Oct 10, 2013 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Mylan Pharms Inc | DOXYCYCLINE HYCLATE | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 091052-001 | Feb 8, 2012 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Mylan Pharms Inc | DIDANOSINE | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 090788-002 | Apr 8, 2010 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Mylan Pharms Inc | ESTRADIOL | estradiol | CREAM;VAGINAL | 208788-001 | Dec 29, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Mylan Pharms Inc | SUMATRIPTAN AND NAPROXEN SODIUM | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 090872-001 | Sep 4, 2018 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Mylan Pharms Inc | OLANZAPINE | olanzapine | TABLET;ORAL | 076866-006 | Apr 23, 2012 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Mylan Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan Pharms Inc | LUXIQ | betamethasone valerate | AEROSOL, FOAM;TOPICAL | 020934-001 | Feb 28, 1999 | 6,126,920 | ➤ Sign Up |
| Mylan Pharms Inc | LUXIQ | betamethasone valerate | AEROSOL, FOAM;TOPICAL | 020934-001 | Feb 28, 1999 | 7,078,058 | ➤ Sign Up |
| Mylan Pharms Inc | OLUX | clobetasol propionate | AEROSOL, FOAM;TOPICAL | 021142-001 | May 26, 2000 | 6,126,920 | ➤ Sign Up |
| Mylan Pharms Inc | EXTINA | ketoconazole | AEROSOL, FOAM;TOPICAL | 021738-001 | Jun 12, 2007 | 7,553,835 | ➤ Sign Up |
| Mylan Pharms Inc | DENAVIR | penciclovir | CREAM;TOPICAL | 020629-001 | Sep 24, 1996 | 5,916,893 | ➤ Sign Up |
| Mylan Pharms Inc | DENAVIR | penciclovir | CREAM;TOPICAL | 020629-001 | Sep 24, 1996 | 5,840,763 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for MYLAN PHARMS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Foam | 2% | ➤ Subscribe | 2009-07-30 |
| ➤ Subscribe | Topical Foam | 0.05% | ➤ Subscribe | 2005-06-27 |
| ➤ Subscribe | Foam | 0.12% | ➤ Subscribe | 2007-08-10 |
International Patents for Mylan Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Singapore | 114493 | ➤ Sign Up |
| Germany | 69122229 | ➤ Sign Up |
| Germany | 3582399 | ➤ Sign Up |
| European Patent Office | 1872776 | ➤ Sign Up |
| Japan | 2008542353 | ➤ Sign Up |
| Mexico | 160431 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for Mylan Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0502314 | 23/1999 | Austria | ➤ Sign Up | PRODUCT NAME: TELMISARTAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; NAT. REGISTRATION NO/DATE: EU/1/98/089/001-010 19981211; FIRST REGISTRATION: BE K (1998) 4288-DE 19981211 |
| 0328535 | 96C0021 | Belgium | ➤ Sign Up | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
| 0812190 | SPC/GB05/042 | United Kingdom | ➤ Sign Up | PRODUCT NAME: MESYLATE, ESYLATE OR SULFATE SALTS OF N-PROPARGYL-1(R)-AMINOINDAN (RASAGILINE); REGISTERED: UK EU/1/04/304/001 20050221; UK EU/1/04/304/002 20050221; UK EU/1/04/304/003 20050221; UK EU/1/04/304/004 20050221; UK EU/1/04/304/005 20050221; UK EU/1/04/304/006 20050221; UK EU/1/04/304/007 20050221 |
| 1412357 | PA2008013 | Lithuania | ➤ Sign Up | PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716 |
| 1663240 | 93382 | Luxembourg | ➤ Sign Up | PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE ET TENOFOVIR ALAFENAMIDE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE DE TENOFOVIR ALAFENAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/16/1112 ODEFSEY - EMTRICITABINE |
| 1280520 | 122015000021 | Germany | ➤ Sign Up | PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
